Follow-up of the effect of BCG vaccine treatment in bladder tumour patients.
The effect of intravesical BCG vaccine treatment in 38 patients with superficial bladder tumour after TUR (Transurethral Resection) was followed by the lymphocyte transformation test (LTT) and the staphylococcus phagocytosis test of in vitro washed leukocytes. The results have confirmed the immunostimulating and hence anti-tumour effect of intravesical BCG vaccine. Monitoring of the cellular immune response is suitable for the continuous follow-up of the BCG effect. Comparing the tolerable side-effects with their favourable therapeutic results, BCG vaccine is considered to be effective for the prevention of recurrences in treating superficial bladder tumours.
Kulcsár
G
G
Institute of Microbiology, Semmelweis University Medical School, Budapest, Hungary.
Nász
I
I
Tenke
P
P
Csata
S
S
D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D010835:Phytohemagglutinins / Q000494:pharmacology; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D010835:Phytohemagglutinins